摘要
由于紫杉醇水溶性差,口服生物利用度低,传统静脉注射给药易导致严重的过敏、嗜中性白血球减少等不良反应。尽管新一代的白蛋白结合型紫杉醇(Abraxane~?)仍然被频繁使用,但静脉注射非常昂贵。笔者就紫杉醇纳米递药系统的研究进展作一综述。
Due to poor solubility and low oral bioavailability of paclitaxel(PTX),traditional intravenous administration can easily cause serious allergies,neutropenia and other adverse reactions.Although a new generation of albumin-bound paclitaxel(Abraxane~?)is still frequently used,intravenous injection is very expensive.The author reviews the research progress of paclitaxel nanometer drug delivery system in this paper.
作者
贵刚
徐勤
GUI Gang;XU Qin(College of Pharmacy,Guilin Medical University,Guilin 541001,China)
出处
《华夏医学》
CAS
2020年第2期175-179,共5页
Acta Medicinae Sinica
基金
国家自然科学基金资助项目(81660668)
